The race to build a safer T-cell engager for solid tumors just got a new, well-funded contender. Crossbow Therapeutics, operating in stealth until now, has secured a $77M venture round to advance its platform of conditionally active bispecific antibodies. The core thesis is addressing the on-target, off-tumor toxicity that has plagued the field; Crossbow's molecules are designed to remain inert in healthy tissue and activate only within the proteolytic tumor microenvironment.
This capital will directly fund the IND-enabling work and planned Phase 1 trials for its lead program, CB-001, a T-cell engager targeting an undisclosed solid tumor antigen. Preclinical data, hinted at in selective presentations, reportedly shows potent tumor cell killing in vivo with a significantly widened therapeutic window compared to a conventional, always-on benchmark. The round's undisclosed investor syndicate suggests sophisticated, data-driven biotech capital convinced by the platform's mechanistic differentiation.
For the sector, this is a clear signal that investor appetite remains strong for novel protein engineering approaches that solve fundamental drug delivery and toxicity problems in immuno-oncology. As first-generation CD3 bispecifics like tebentafusp prove the modality's potential in solid tumors, the next wave of investment is flowing into companies like Crossbow that aim to build in critical safety switches from the ground up.